t
Proteome Sciences plc announced on April 1, 2022, a director shareholding notification for Non-Executive Director Martin Diggle. The notification detailed the transfer of 52,445,715 ordinary shares at 0p per share to a new custodian on March 28, 2022. This relates to the holding of Vulpes Life Sciences Fund, which remains unchanged at 65,826,194 ordinary shares, representing 22.3% of Proteome Sciences' share capital.
| Date | 1 Apr 2022 |
| Time | 18:01:45 |
| Category | Director/PDMR dealings |
| ID | 0495H |
1 April 2022
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Director shareholding
The Company has been notified that the shareholding of Vulpes Life Sciences Fund ("Vulpes") remains unchanged at 65,826,194 ordinary shares, representing 22.3 per cent of the share capital, but that the holding has been transferred to a new custodian to hold the shares on Vulpes' behalf.
Martin Diggle, Non-Executive Director of Proteome Sciences, is a director and partner of Vulpes Investment Management Private Limited which manages Vulpes. Accordingly, the notification table below in regard to Martin Diggle is made in accordance with the requirements of the UK Market Abuse regulation.
For further information please contact:
|
Proteome Sciences plc Mariola Soehngen, M.D., Chief Executive Officer |
|
|
Dr Ian Pike, Chief Scientific Officer Richard Dennis, Chief Commercial Officer |
Tel: +44 (0)20 7043 2116 |
|
|
|
|
Allenby Capital Limited (AIM Nominated Adviser & Broker) |
|
|
John Depasquale / Jeremy Porter |
Tel: +44 (0) 20 3328 5656 |
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
|
1. |
Details of the person discharging managerial responsibilities/person closely associated |
|||||
|
a) |
Name: |
Martin Diggle |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status: |
Non-Executive Director |
||||
|
b) |
Initial notification/Amendment: |
Initial Notification |
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name: |
Proteome Sciences Plc |
||||
|
b) |
LEI: |
213800Q62ICXANKU2986 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument: Identification code: |
Ordinary Shares of 1p nominal value GB0003104196 |
||||
|
b) |
Nature of the transaction: |
Transfer of registered holding to new custodian |
||||
|
c) |
Price(s) and volume(s): |
|
||||
|
d) |
Aggregated information: · Aggregated volume: · Price: |
Same as 4c) above.
|
||||
|
e) |
Date of the transaction: |
28 March 2022 |
||||
|
f) |
Place of the transaction: |
Outside a trading venue |
||||